Research programme: Alzheimer's disease therapeutics - Pain Therapeutics

Drug Profile

Research programme: Alzheimer's disease therapeutics - Pain Therapeutics

Alternative Names: PTI-125

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pain Therapeutics
  • Class Antidementias; Small molecules
  • Mechanism of Action Microfilament protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 31 Jul 2017 US FDA approves IND application for PTI 125 in Alzheimer's disease
  • 31 Jul 2017 Pain Therapeutics plans a phase I trial for Alzheimer's disease
  • 05 Jun 2017 Pain Therapeutics announces intention to submit an IND application with the US FDA for PTI 125, in the third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top